Decoding Alzheimer’s: The Arctic Mutation’s Role in Unusual Brain Structures
Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
eLife4d
Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production
This manuscript provides fundamental studies to help us better understand the effects of mutations in the presenilin-1 (PSEN1) gene on proteolytic processing of the amyloid precursor protein (APP).
FierceBiotech4d
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
GlobalData on MSN4d
Alector stock drops after Alzheimer’s drug fails in Phase II trial
"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
ALS News Today1d
Brain scans may predict ALS risk in C9ORF72 mutation carriers
Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...
BioSpace4d
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
News Medical on MSN3d
TRiC mutations found to cause developmental brain malformations in children
In 1992, Judith Frydman, PhD, discovered a molecular complex with an essential purpose in all of our cells: folding proteins correctly.
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
News Medical4d
TRiC mutations found to cause developmental brain malformations in children
Although dysfunctions in the complex are linked to cancer and Alzheimer's disease, germline mutations -; mutations present in all cells in an organism -; in TRiC had never been implicated in a ...
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Alector, Inc.: Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...